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Abstract: Diabetic macular edema (DME) is the main cause of visual impairment associated with 
diabetic retinopathy (DR) and macular laser, during approximately three decades, and was the 
single treatment option. More recently, intravitreous injections of anti-angiogenics and corticoster-
oids modified the treatment paradigm associated with significant vision improvements. 
Nevertheless, not all patients respond satisfactorily to anti-VEGF or corticosteroid injections, so 
an adequate treatment choice and a prompt switch in therapeutic class is recommended. Several 
algorithms and guidelines have been proposed for treating center involving DME to improve 
patients’ vision and quality of life. However, in Portugal, such guidelines are lacking. The present 
review aimed to provide guidelines for the treatment options and patient monitorization in the 
management of center-involving DME. We recommend anti-vascular endothelial growth factor 
(VEGF) as first-line therapy after a clinical evaluation accompanied by a rigorous metabolic 
control. Depending on the response obtained after 3–6 monthly intravitreal injections we suggest 
switching outside the class in case of a non-responder, maintaining the anti-VEGF-therapy in 
responders to anti-angiogenics. The treatment regimen for Dexamethasone intravitreal implant 
(DEXii) should be pro-re-nata with bi-monthly or quarterly monitoring visits (with a scheduled 
visit at 6–8 weeks after DEXii for intraocular pressure control). If a patient does not respond to 
DEXii, switch again to anti-VEGF therapy, combine therapies, or re-evaluate patients diagnose. 
There is a resilient need to understand the disease, its treatments, regimens available, and 
convenience for all involved to propose an adequate algorithm for the treatment of diabetic 
retinopathy (DR) and DME in an individualized regimen. Further understanding of the contributing 
factors to the development and progression of DR should bring new drug discoveries for more 
effective and better-tolerated treatments. 
Keywords: anti-vascular endothelial growth factor, center-involving diabetic macular 
edema, dexamethasone intravitreal implant, diabetic retinopathy
Introduction
Diabetic macular edema (DME) commonly leads to impairment of visual acuity in 
patients with non-proliferative diabetic retinopathy (NPDR) and is more prevalent 
in patients with type 2 diabetes mellitus (DM2) than type 1 (DM1), accounting to 
nearly 12.9% and 7.86% cases, respectively.1 The causes of DME are multifactor-
ial; however, the predominant reason is attributable to blood–retinal barrier break-
down that leads to swelling in the Henle’s layer of the macula.2
Diabetic retinopathy (DR) and DME are currently treated with a rigorous 
systemic and ocular management.2 Controlling glucose, blood pressure, and blood 
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lipids, as well as other multifactorial interventions, are 
important elements of systemic treatment.3 One of the 
goals for successful management of diabetes and its con-
sequences is to maintain HbA1c levels between 6% and 
7%. Because a high blood glucose level is the most mod-
ifiable risk factor, educating the patient to a healthy life-
style with good control of their disease is important for 
blood glucose levels, blood pressure, and serum lipid 
levels.3,4 The primary care doctor, nurse, endocrinologist, 
and ophthalmologist should all be actively involved in this 
control and monitoring.
In terms of ocular treatment, there are presently 
a variety of pharmacological and non-drug options avail-
able, albeit none of them cure the diseases, but only 
ameliorate symptoms and delay disease progression.3 The 
most current and available treatment options are laser 
photocoagulation, pharmacological agents injected in the 
vitreous body, namely anti-VEGF and corticosteroids, and 
vitrectomy.2
Laser photocoagulation was one of the first non- 
invasive treatments to have a low rate of complications 
and a high rate of success. The Early Treatment Diabetic 
Retinopathy Study (ETDRS) was a landmark clinical trial 
that demonstrated the efficacy of the focal macular laser in 
the treatment of diabetic retinopathy and diabetic macular 
edema (DME).5 The criteria for treating “clinically signif-
icant macular edema” (CSME) were defined in this study, 
and they were used to determine which patients should be 
treated with macular laser.6 According to the ETDRS, 
laser photocoagulation reduced the probability of moderate 
vision loss by around 50% and improved the vision of 
around 30% of the patients. However, despite photocoa-
gulation treatment, patients still experience vision loss.6 To 
date, there has been a substantial shift in the type of laser 
treatments from traditional lasers to more advanced tech-
nologies, such as micropulses, which have increased the 
therapeutic benefits of laser use while reducing retinal 
damage.7 Unlike conventional lasers, subthreshold micro-
pulse laser treatment does not damage neurosensorial ret-
inal cells. The importance of laser photocoagulation 
complications has lessened with the development of 
newer lasers, but the principle of thermal destruction of 
retinal cells has stayed unchanged. Several investigations 
have shown that subthreshold micropulse laser treatment is 
safe and does not damage the retinal pigment epithelium 
or photoreceptors.8,9
It should be noted, therefore, that the morphological 
improvement is greater than the functional improvement 
and because of this, pharmacological treatments such as 
anti-VEGF and corticosteroids are often considered for 
DME, with functional benefits superior to subthreshold 
micropulse laser treatment.10,11 According to Euretina 
guidelines, laser photocoagulation is not recommended 
for the treatment of DME.4 Nevertheless, in certain cir-
cumstances, subthreshold micropulse laser treatment may 
be considered when other therapies are unavailable or 
contraindicated, such as during pregnancy or breastfeed-
ing, or when other treatments are ineffective.
The development of new treatment options and diag-
nostics tools has significantly improved the management 
of DME.
The pharmacological treatments primarily include anti- 
vascular endothelial growth factor (VEGF) medications 
and corticosteroids. The former includes aflibercept 
(Eylea®; Regeneron Pharmaceuticals Inc., Tarrytown, 
NY, USA, and Bayer HealthCare Pharmaceuticals, 
Berlin, Germany), ranibizumab (Lucentis®; Genentech 
Inc., South San Francisco, CA, USA), and bevacizumab 
(Avastin®; Genentech, South San Francisco, CA, USA/ 
Roche, Basel, Switzerland), which is an off-label 
therapy.12 VEGF inhibition has been widely used and has 
established itself as the gold standard for the treatment of 
DR associated with DME.12
Aflibercept, also known as VEGF-Trap, is a fusion 
protein that combines the ligand-binding components of 
VEGFR-1 and VEGFR-2 extracellular domains with the 
Fc part of IgG. This anti-angiogenic inhibits tumor growth 
and vascularization.13 Furthermore, this anti-VEGF binds 
to all VEGF-A, VEGF-B, and PlGF isoforms.13
Ranibizumab is a recombinant humanized monoclonal 
antibody fragment (Fab) generated in an Escherichia coli 
production system (and thus not glycosylated). It was 
genetically modified to maximize its affinity for binding 
and inhibition of VEGF-A, and it was specially developed 
to be used intravitreally, having been licensed by the FDA 
and EMA for the treatment of several retinal disorders.14
Bevacizumab is approved for the treatment of patients 
with metastatic colon, rectum, or breast cancer, as well as 
individuals with non-small cell lung cancer or metastatic 
renal cell carcinoma. However, it is utilized off-label in 
ophthalmology. It is a full-length recombinant humanized 
monoclonal antibody with both Fc and Fab regions that is 
three times larger than ranibizumab being generated in the 
mammalian expression system (glycosylated molecule). 
The Fc antibody domain contributes to immune 
activation.14
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In the DRCRnet clinical trials, specifically in the 
T protocol, which compared the 3 anti-angiogenic drugs, 
Eylea® (aflibercept), Lucentis® (ranibizumab), and 
Avastin® (bevacizumab) in the treatment of DME, patients 
with visual acuity of 20/50 or worse at the start of the 
study had superior outcomes with aflibercept at the end of 
the first year. However, there were no differences in 
results between the three drugs at the end of the 
first year in patients with baseline vision of 20/40 to 20/ 
32. At the end of protocol T second year, the only statis-
tical difference in acuity among the three drugs was afli-
bercept’s superiority to bevacizumab in eyes with 20/50 or 
worse baseline vision. Furthermore, there were no signifi-
cant differences regarding drug safety between bevacizu-
mab, ranibizumab, and aflibercept in the treatment of 
DME. Notwithstanding, not all patients respond suffi-
ciently to anti-VEGF therapy, prompting clinicians to 
switch to other available therapies or novel research 
approaches.15
The latter include Dexamethasone intravitreal implant 
(DEXii), (Ozurdex®; Allergan Inc., Irvine, CA), an inject-
able fluocinolone polymer (FAc), (Iluvien®; Alimera 
Sciences, Alpharetta, GA), and triamcinolone acetonide 
(TA) (an off-label therapy).16
Corticosteroids have a significant role in the treatment 
of DME. Despite the many benefits of intravitreous steroid 
therapy, this treatment is associated with the risk of 
adverse events such as increased intraocular pressure and 
cataract formation.16 The role of corticosteroids in the 
treatment of DME is multifactorial. Corticosteroids are 
potent anti-inflammatory drugs that also antagonize 
VEGF-A function, inhibit leukostasis, and reduce inflam-
matory cytokines.17 DEXii was created to ensure 
a continuous release of the medication into the vitreous 
for approximately 4 to 6 months.18 DEXii is 
a biodegradable implant that contains 0.7 mg DEX and is 
made of polyglycolic acid and polylactic acid polymers 
and has been shown to be effective in treating a variety of 
retinal disorders, including ME, DME, and retinal vein 
occlusion.18 FAc is a nonbiodegradable implant that con-
tains 0.19 mg of FAc and is meant to deliver 0.20 μg of 
FAc per day for three years.19
As corticosteroids trigger cataract development in 
phakic eyes, the visual results may be distorted by cataract 
progression. Nevertheless, according to a subgroup analy-
sis of pseudophakic eyes in Protocol I of the Diabetic 
Retinopathy Clinical Research (DRCR) network at two 
years, the results of the triamcinolone acetonide arm 
were equivalent to the ranibizumab arms.20 IOP is another 
side effect of corticosteroids; however, it is usually trea-
table with intraocular drops.21
Despite the well-known adverse events of corticoster-
oids, such as cataract formation and increased intraocular 
pressure, efficacy had already shown that the benefits may 
outweigh in specific cases of the risks. Furthermore, intra-
vitreal corticosteroids provide a significant advantage 
since the systemic side effects of intra-ocular administered 
corticosteroids occur rarely.21
Several randomized controlled trials (RCTs) have 
reported the success of DEXii, aflibercept, and ranibizu-
mab, and these are now approved for this indication by the 
Food and Drug Administration (FDA), European 
Medicines Agency (EMA), and other regulatory authori-
ties throughout the world.18–23 Many protocols, algo-
rithms, clinical trials, and observational studies have 
resulted in an extreme variety of treatment regimens and 
patient’s follow-up options; however, these are sometimes 
not well adapted to clinical practice. Furthermore, clear 
guidelines for Portuguese ophthalmologists to address 
patients’ treatment options and follow-up, besides what is 
stated in the summary product characteristics, in the real- 
world studies, in the countries’ guidelines and published 
by international ophthalmology organizations, are limited. 
Therefore, the present review was aimed to provide guide-
lines for the treatment options and patient monitorization 
in the management of center-involving DME.
Materials and Methods
Literature Search Strategy
Literature describing the management of DME was 
searched from PubMed and Google Scholar. The papers 
chosen were published between 2010 and 2020. Only peer- 
reviewed publications were included in the selection of 
papers, which were all written in the English language. 
The keywords for the search included “management of 
diabetic macular edema”, OR “diabetic retinopathy”, OR 
“anti-vascular endothelial growth factor”, OR “Ozurdex”, 
OR “dexamethasone intravitreal implant”, OR “Iluvien” 
OR “fluocinolone acetonide intravitreal implant”, in the 
title or the manuscript text. Only human research was 
included and remains were excluded. In addition, the 
references of relevant papers were examined for complete-
ness of our search and also to include new studies, addi-
tional important data, and guidelines.
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Data Extraction, Quality Assessment, and 
Endpoints
The titles and abstracts were examined by two researchers 
independently, and full articles were chosen for inclusion.
All authors read and analysed the articles selected for 
inclusion in the article, and they were judged to be appropriate 
for inclusion in this manuscript based on the major objectives 
or endpoint of this recommendation. Disagreements were 
settled by discussion and agreement. Moreover, the findings 
of all the relevant articles were collected, comprehensively 
analysed, and discussed by a group of retinal experts.
Data Analysis
Information retrieved was analysed and discussed equally 
by all authors, during consensus meetings. No statistical 
analysis was carried out for this guideline.
Discussion
Treatment Options
The intravitreal levels of VEGF are reportedly higher in 
patients with diabetes.24 Therefore, intravitreal anti-VEGF 
medications, such as ranibizumab, aflibercept, and bevacizu-
mab are usually the first line of treatment for DME. Anti- 
VEGF-based treatment regimen is continued if the patient 
responds well; however, the strategy is moved to intravitreal 
corticosteroids, normally DEXii when the patient does not 
respond to anti-VEGF-based treatment even after 3–6 monthly 
intravitreal injections. DEXii is also preferred for patients not 
suitable for first-line VEGF therapy or those who are unavail-
able for frequent check-ups, while FAc has been used for more 
chronic and resistant DME or when a very long steroid action is 
desired. The pro-re-nata (PRN) treatment regimen should 
include bimonthly or quarterly eye check-ups and intraocular 
pressure control (IOP) control in patients at 2 months after each 
DEXii. In cases where steroid treatment is not effective, the 
course should involve switching again to anti-VEGF-based 
strategy with or without combination therapy, including laser 
with ETDRS protocol 2007 or more retina-friendly laser para-
meters and if needed, re-evaluation of the diagnostic can be 
performed.25,26
Factors Affecting Treatment
Patients with diabetes having DME or proliferative dia-
betic retinopathy (PDR) have higher risk of cardiovascular 
diseases, and arteriothrombotic events, such as stroke or 
myocardial infarction.27 Therefore, evaluation of patients’ 
medical history, including diabetes status, cardiovascular 
events, and other comorbidities, is imperative. Anti-VEGF 
are not forbidden in these cases. However, the risk-benefit 
should be discussed and evaluated case by case.
Ophthalmologic Factors
Proliferative Diabetic Retinopathy
Anti-VEGF agents, aflibercept and ranibizumab and the 
off-label use of bevacizumab, should be the 1st line treat-
ment option in eyes with DME associated with PDR, as 
suggested by the regression in neovascularization in the 
RISE and RIDE, RESOLVE, RESTORE and RETAIN, 
VIVID and VISTA.28
Vitrectomized Eyes
DEXii can be used as 1st line therapy in vitrectomized 
patients. These have been found useful, especially in treat-
ing inflammation and ME in difficult-to-treat vitrecto-
mized eyes, showing vascular leakage and best corrected 
visual acuity (BCVA) improvement.29,30
Tractional Edema
Based on the literature and real-world experience we can 
recommend PPV plus DEXii as first-line therapy when 
traction is present. It has shown improvements in BCVA, 
central retinal thickness and macular volume with no 
apparent hemorrhage or trauma to the retina, as well as 
decreased macular edema and improved visual outcome 
after macular epiretinal membrane removal.31,32
Intraocular Pressure
We recommend following the proposed algorithm in case of 
controlled IOP (Figure 1). However, in case of uncontrolled 
IOP, the 1st line treatment should include anti-VEGF and 
DEXii should be considered after discussion of the risk- 
benefit. Anti-VEGF is preferable in patients with uncontrolled 
or severe glaucoma (double or triple combination therapy). 
Conversely, DEXii and FAc are acceptable in patients with no 
glaucoma or glaucoma treated with monotherapy.21,33,34
Nevertheless, after DEXii patients should perform a safety 
visit after 6–8 weeks of implantation to evaluate the therapeutic 
response to corticosteroids and any potential increase in IOP.33
Inflammation Biomarkers
Several inflammatory retinal biomarkers have been pro-
posed to identify DME cases where the inflammatory 
pathway is prominent.35 The image biomarkers mostly 
studied include disorganization of retinal inner layers 
(DRIL), subretinal fluid (SRF), hyperreflective retinal 
spots (HRS), hard exudates (Figure 2).36–39
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Figure 1 Proposed algorithm for the treatment of CiDME. 
Abbreviations: Anti-VEGF, anti-vascular endothelial growth factor; ATEs, arterial thromboembolic events; CiDME, center involved DME; CMT, center macular thickness; 
CVC, cardiovascular diseases; DEXii – dexamethasone intravitreal implant; FAc, fluocinolone acetonide intravitreal implant; IOP, intraocular pressure; NVC, neovasculariza-
tion; PRN, pro-re-nata or as needed; TT, treatment.
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Meduri et al investigated the safety and efficacy of 
DEXii as first-line therapy in DME-naïve patients, demon-
strating the importance of OCT biomarkers as predictors 
of response. The existence of SRD, the integrity of EZ 
(ellipsoid zone), and the lack of vitreomacular abnormal-
ities were predictors of a positive response to DEXii.40
Probably, intravitreous corticosteroids can be a good 
treatment option in the presence of such biomarkers, but 
additional studies are needed to confirm this theory.
Lens Status and Age
Lens status should be evaluated before patients’ treatment 
with any class of corticosteroids. Depending on lens status, 
aphakic, or age, the recommendation for therapy varies. 
The studies with corticosteroids intravitreous implants for 
DME have reported cataract-associated adverse events in 
phakic eyes and increased vision loss in patients treated 
with DEX or FAc.41,42 Therefore, in a young and phakic 
patient, we recommend first-line anti-VEGF treatment; 
however, in a pseudophakic patient or a patient with 
a scheduled cataract surgery DEXii as first-line treatment 
can be considered. For aphakic patients or those without 
capsular or zonular integrity, we recommend anti-VEGF as 
first-line treatment due to the risk of the corticosteroids 
implant migration to the anterior chamber.43
Ischemia
In cases of DME with macular ischemia associated, the 
therapeutic options remain controversial. Multicenter stu-
dies confirmed the efficacy of anti-VEGFs in DME how-
ever, have excluded eyes with macular ischemia, so it is 
not possible to conclude about the efficacy of these drugs 
in these specific cases. Although the ETDRS study recom-
mends laser photocoagulation in those cases, the visual 
prognosis is worse than without ischemia, and some 
authors do not even recommend it.44,45
Despite the poor prognosis, it is suggested to treat patients 
with anti-VEGF drugs, monitor the visual acuity and the 
evolution of the DME with OCT monthly. If there is no 
improvement in visual acuity after the edema resolution, 
treatment should be suspended. Intravitreous corticosteroids 
may be an alternative in cases where anti-VEGFs are contra-
indicated or when the latter has proven ineffective in redu-
cing DME. As with anti-VEGFs, also in these cases, if the 
resolution of the DME is not accompanied by recovery of 
visual acuity, treatment should be discontinued.46
Systemic Factors
Recent Cardiovascular Disease (CVD)/Recent 
Arteriothromboembolic Events
There is a proven correlation between diabetes and 
CVD.47 The diabetic population has several risk factors 
that contribute to the development of CVD, such as hyper-
tension, abnormal cholesterol, and high triglycerides 
values, obesity, lack of physical activity, smoking habits 
and lastly poor controlled blood sugar levels.47 Anti- 
VEGF agents can potentially increase systemic adverse 
events such as kidney disease, gastrointestinal perfora-
tions, hypertension, stroke, myocardial infarction, and 
thromboembolic events, due to which a black box has 
been added in the summary of product characteristics of 
bevacizumab, ranibizumab, and aflibercept.48,49
Based on the evidence published concerning the long- 
term systemic safety profile of corticosteroids, we recom-
mend DEXii as first-line therapy amid corticosteroids.
Pregnancy/Breastfeeding
DME treatment during pregnancy may be difficult owing 
to questions regarding the potential adverse antiangiogenic 
effects of anti-VEGF therapies on a developing fetus.50
If DME is present during the pregnancy, observation is 
a reasonable management option for pregnant patients 
Figure 2 OCT biomarkers in DME: A. Subretinal fluid (SRF), B. Hyperreflective retinal spots (HRS), C. Intraretinal cysts (IRC), D. Disorganization of retinal inner layers 
(DRIL), E. Hard exudates. Courtesy Ana Rita Santos.
https://doi.org/10.2147/OPTH.S318026                                                                                                                                                                                                                               
DovePress                                                                                                                                                                 
Clinical Ophthalmology 2021:15 3226
Figueira et al                                                                                                                                                          Dovepress






























































with mild DME, since the edema may well resolve after 
delivery. For DME requiring treatment, we believe for 
safety reasons that anti-VEGF therapy should be avoided 
in favor of focal laser photocoagulation or DEXii.51,52
Other Factors for Treatment Decision: Patient 
Compliance
Although continuity with treatment is essential for its 
success, compliance with frequent anti-VEGF injections 
is a recognized problem with this paradigm regarding 
recurrent neovascularization and hemorrhage. Evaluating 
patient’s willingness to adhere to health care provider’s 
recommendations is a key factor.53,54 The introduction of 
longer duration-of-action anti-VEGF drugs, currently 
under development for DME, such as faricimab or brolu-
cizumab, may lower the number of requested injections 
and follow-up visits, improving patient’s compliance.
Therefore, in cases of non-compliance or impossibility 
due, for example, to socio-economic reasons, to return to 
treatment or follow-up visits we can recommend DEXii as 
first-line treatment.
Treatment Regimens and Monitorization
Anti-VEGFs are normally used in PRN regimen after 3 to 
6 monthly intravitreal injections, or in fixed regimens or in 
a treat and extend (TE) approach. Monitoring, either clin-
ical or imagiological must be adjust to each treatment 
regimen.34,55 The treatment regimen for DEXii should be 
the PRN with bi-monthly or quarterly monitoring visits 
(with a safety visit at 6–8 weeks after DEXii for IOP 
control). After injecting FAc patient should be monitored 
at least quarterly to rule out possible side effects. If 
a patient does not respond to corticosteroids, switch 
again to anti-VEGF therapy, combine therapies or re- 
evaluate patients diagnose (Figure 1).
Conclusion
There are significant unmet needs in the current management 
of DME. With a significant proportion of patients not 
responding to the first-line anti-VEGF therapy, it is important 
to identify non-responders through inflammatory biomarkers 
to provide the most efficacy therapy for each patient in 
individualized treatment.34 We have tried to bring together 
the scientific knowledge from randomized clinical trials, with 
real-world studies and our clinical experience. The manage-
ment of DME requires the work of a multidisciplinary team 
to achieve treatment optimization and maximizing outcomes.
Several algorithms and guidelines have been proposed 
for the treatment of this multifactorial disease to improve 
patients’ vision and quality of life for all involved. 
Figure 1 highlights our recommendation for an optimized 
treatment. There is a resilient need to understand the dis-
ease, its treatments, regimens available and convenience 
for all involved to propose an adequate algorithm for the 
treatment of DR and DME in an individualized regimen.
Despite the emergence of consensus guidelines as well 
as algorithms, DR and DME remain challenging to treat.
Innovative therapies approaches are in the pipeline to 
improve compliance, extending the duration of action and 
thus reducing the need for frequent injections and to 
improve optimization of the functional and anatomical, 
such as the port delivery systems with ranibizumab 
(Genentech/Roche, Phase III, VEGF-A antagonist), brolu-
cizumab (Novartis, Phase III, VEGF-A antagonist), farici-
mab (Genentech/Roche, Phase III, VEGF-A antagonist), 
KSI-301 (Kodiak Sciences Inc., Phase III, VEGF antago-
nists), MYL-1701P (Momenta Pharmaceuticals/Mylan, 
Phase III, VEGF-A antagonist) and Gene Therapy among 
others.56–61
Further understanding of the contributing factors to the 
development and progression of DR should bring new 
drug discoveries for more effective and better-tolerated 
treatments.
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